Effects of optimized heart failure therapy and anemia correction with epoetin β on left ventricular mass in hemodialysis patients

American Journal of Nephrology

Volumn 25, Issue 3, 2005, Pages 211-220

  Hampl, Hannelore ^a,d   Hennig, Lars ^a   Rosenberger, Christian ^a   Amirkhalily, Masoud ^a   Gogoll, Lutz ^a   Riedel, Eberhard ^b   Scherhag, Armin ^c  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d Dialysis Center   (Germany)

Author keywords

Anemia management; Heart failure therapy; Hemodialysis; Left ventricular hypertrophy

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEMODIALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADRENERGIC BETA-ANTAGONISTS; ANEMIA; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIAC OUTPUT, LOW; CARDIOVASCULAR AGENTS; ECHOCARDIOGRAPHY; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HEMODYNAMIC PROCESSES; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; IRON; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENAL DIALYSIS; STROKE VOLUME; TREATMENT OUTCOME;

EID: 23944523848     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000085881     Document Type: Article

References (59)

1. Longenecker JC, Coresh J, Powe NR, Levey AS, Fink NE, Martin A, Klag MJ: Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: The CHOICE Study. J Am Soc Nephrol 2002;13:1918-1927.
2. Zoccali C, Mallamaci F, Tripepi G: Novel cardiovascular risk factors in end-stage renal disease. J Am Soc Nephrol 2004;15:S77-S80.
3. Sarnak MJ: Cardiovascular complications in chronic kidney disease. Am J Kidney Dis 2003;41:S11-S17.
4. Cheung AK, Sarnak MJ, Yan G, Berkoeben M, Heyka R, Kaufmann A, Lewis J, Rocco M, Toto R, Windus D, ORNT D, Levey AS, for the HEMO Study Group: Cardiac disease in maintenance hemodialysis patients: Results of the HEMO Study. Kidney Int 2004;65:2380-2389.
5. Kalantar-Zadeh K, Block G, Humphreys MH, Kopple JD: Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int 2003;63:793-808.
6. Silberberg JS, Barre PE, Prichard SS, Sniderman AD: Impact of left ventricular hypertrophy on survival in end-stage renal disease. Kidney Int 1989;36:286-290.
7. Foley NF, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE: The prognostic importance of left ventricular geometry in uremic cardiomyopathy. J Am Soc Nephrol 1995;5:2024-2031.
8. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE: The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am J Kidney Dis 1996;28:53-61.
9. Foley RN, Parfrey PS, Kent GM, Harnett JD, Murray DC, Barre PE: Serial change in echocardiographic parameters and cardiac failure in end-stage renal disease. J Am Soc Nephrol 2000;11:912-916.
10. Zoccali C, Benedetto FA, Mallamaci F, Tripepi G, Giacone G, Stancanelli B, Cataliotti A, Malatino LS: Left ventricular mass monitoring in the follow-up pf dialysis patients: Prognostic value of left ventricular hypertrophy progression. Kidney Int 2004;65:1492-1498.
11. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP: Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990;322:1561-1566.
12. Koren MJ, Devereux RB, Casale PN, Savage DD, Laagh JH: Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 2001;114:345-352.
13. Benjamin EJ, Levy D: Why is left ventricular hypertrophy so predictive of morbidity and mortality? Am J Med Sci 1999;317:168-175.
14. Devereux R, Reichek N: Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation 1977;55:1325-1350.
15. Devereux RB, Lutas EM, Casale PN, Kligfield P, Eisenberg RR, Hammond IW, Miller DH, Reis G, Aldermann MH, Laragh JH: Standardization of M-mode echocardiographic left ventricular anatomic measurements. J Am Coll Cardiol 1984;4:12-1230.
16. Berger AK, Duval S, Krumholz HM: Aspirin, β-blocker, and angiotensin-converting enzyme therapy in patients with end-stage renal disease and acute myocardial infarction. J Am Coll Cardiol 2003;42:209-210.
17. Tonelli M, Bohm C, Pandeya S, Gill J, Levin A, Kiberd BA: Cardiac risk factors and the use of cardioprotective medications in patients with chronic renal insufficiency. Am J Kidney Dis 2001;37:484-489.
18. Griffith TF, Chua BSY, Allen AS, Klassen PS, Reddan DN, Szczech LA: Characteristics of treated hypertension in incident hemodialysis and peritoneal dialysis patients. Am J Kidney Dis 2003;42:1260-1269.
19. Herzog CA, Ma JZ, Collins AJ: Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. N Engl J Med 1998;339:799-805.
20. Trespalacios FC, Taylor AJ; Agodoa LY, Bakris GL, Abbott KC: Heart failure as a cause for hospitalization in chronic dialysis patients. Am J Kidney Dis 2003;41:1267-1277.
21. Canella G, La Canna G, Sandrini M, Gaggiotti M, Nordio G, Movilli E, Mombelloni S, Visioli O, Maiorca R: Reversal of left ventricular hypertrophy following recombinant human erythropoietin treatment of anemic dialyzed uremic patients. Nephrol Dial Transplant 1991;6:31-37.
22. Canella G, Paoletti E, Delfino R, Peloso G, Molinari S, Traverso GB: Regression of left ventricular hypertrophy in hypertensive dialyzed uremic patients on long-term anti-hypertensive therapy. Kidney Int 1993;44:881-886.
23. Canella G, Paoletti E, Delfino R, Peloso G, Rolla D, Molinari S: Prolonged therapy with ACE inhibitors induces a regression of left ventricular hypertrophy of dialyzed uremic patients independently from hypotensive effects. Am J Kidney Dis 1997;30:659-664.
24. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA: The effects of normal versus low treated hematocrit values in hemodialysis patients with cardiac disease with erythropoietin. N Engl J Med 1998;339:584-490.
25. Foley RN, Parfrey PS, Morgan J, Barre PE, Campbell P, Cartier P, Coyle D, Fine A, Handa P, Kingma I, Lau CY, Levin A, Mendelssohn D, Muirhead N, Murphy B, Plante RK, Posen G, Wells GA: Effects of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int 2000;58:1325-1335.
26. London GM, Pannier B, Guerin AP, Blacher J, Marchais SJ, Darne B, Metivier F, Adda H, Safar ME: Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: Follow-up of an interventional study. J Am Soc Nephrol 2001;12:2759-2767.
27. Cice G, Ferrara L, D'Andrea A, D'Ilsa S, Di Benedetto A, Cittadini A, Russo PE, Golino P, Calabro R: Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy. J Am Coll Cardiol 2003;41:1438-1444.
28. Kanno Y, Kaneko K, Kaneko M, Kotaki S, Mimura T, Takane H, Suzuki H: Angiotensin receptor antagonist regresses left ventricular hypertrophy associated with diabetic nephropathy in dialysis patients. J Cardiovasc Pharmacol 2004;43:380-386.
29. Foley RN, Parfrey PS, Kent GM, Harnett JD, Murray DC, Barre PE: Long-term evolution of cardiomyopathy in dialysis patients. Kidney Int 1998;54:1720-1725.
30. Sahn DJ, Demaria A, Kisslo J, Weyman A: The committee on M-mode standardization of the American Society of Echocardiography. Recommendations regarding quantitation in M-mode echocardiographic measurements. Circulation 1978;58:1072-1083.
31. US Renal Data System, USRDS 2002 Annual Data Report; in Atlas of End-Stage Renal Disease in the United States. Bethesda, NIH, National Institute of Diabetes and Digestive and Kidney Disease, 2002.
32. Foley RN, Parfrey PS, Sarnak MJ: Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998;32(suppl 3):S112-S119.
33. Harnett JD, Foley RN, Kent GM, Barre PE, Murray D, Parfrey PS: Congestive heart failure in dialysis patients: Prevalence, incidence, prognosis and risk factors. Kidney Int 1995;47:884-890.
34. Schreiber BD: Congestive heart failure in patients with chronic kidney disease and on dialysis. Am J Med Sci 2003;325:179-193.
35. Remme WJ, Swedberg K: Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001;22:1527-1560.
36. Hunt SA, Baker DW, Chin MH, Cinquegrani MP, Feldman AM, Francis GS, Ganiats TG, Goldstein S, Gregoratos G, Jessup ML, Noble RJ, Packer M, Silver MA, Stevenson LW, Gibbons RJ, Antman EM, Alpert JS, Faxon DP, Fuster V, Gregoratos G, Jacobs AK, Hiratzka LF, Russell RO, Smith SC Jr: ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult. Circulation 2001;104:2996-3007.
37. McMurray JJV, Östergren J, Swedberg K, Granger CB, Held P, Michelson EL, Olofsson B, Yusuf S, Pfeffer MA (CHARM-Added): Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: The CHARM-Added Trial. The Lancet 2003;362:767-771.
38. Yusuf S, Maggioni AP, Held P, Rouleau JL: Effects of candesartan, enalapril or their combination on exercise capacity, ventricular function, clinical deterioration and quality of life in heart failure (RESOLVD). Circulation 1997;96(suppl 1):1-452.
39. Doggrell SA, Wanstall JC: Vascular chymase: Pathophysiological role and therapeutic potential of inhibition. Cardiovasc Res 2004;61:653-662.
40. Dell'Italia LJ, Husain A: Dissecting the role of chymase in angiotensin II formation and heart and blood vessel disease. Curr Opin Cardiol 2002;17:374-379.
41. Vlahakos DV, Hahalis G, Vassilakos P, Marathias KP, Geroulanos S: Relationship between left ventricular hypertrophy and plasma renin activity in chronic hemodialysis patients. J Am Soc Nephrol 1997;8:1764-1770.
42. Hausberg M, Kosch M, Harmelink P, Barenbrock M, Hohage H, Kisters K, Dietl KH, Rahn KH: Sympathetic nerve activity in end-stage renal disease. Circulation 2002;106:1974-1979.
43. Conn JN, Tognoni G: A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure (ValHEFT). N Engl J Med 2001;345:1667-1675.
44. Pfeffer MA, McMurray JJV, Velazquez EJ, Ruleau JL, Kober L, Maggioni AP, Solomon SD, Swedberg K, Van de Werf F, White H, Leimberger JD, Hennis M, Edwards S, Zelekofske S, Sellers MA, Califf RM (VALIANT): Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349:1893-1906.
45. Amann K, Buzello M, Simonaviciene A, Miltenberger-Miltenyi G, Koch A, Nabokov A, Gross ML, Gless B, Mall G, Ritz E: Capillary/myocyte mismatch in the heart in renal failure - a role for erythropoietin? Nephrol Dial Transplant 2000;15;964-969.
46. Tomanek RJ: Sympathetic nerves modify mitochondrial and capillary growth in normotensive and hypertensive rats. J Mol Cell Cardiol 1989;21:755-764.
47. Abbott KC, Trespalacios FC, Agodoa LY, Taylor AJ, Bakris GL: Beta-blocker use in long-term dialysis patients: Association with hospitalized heart failure and mortality. Arch Intern Med 2004;164:2465-2471.
48. National Kidney Foundation: K/DOQI Clinical Practice Guidelines. Am J Kidney Dis 2001;37:S5-S35.
49. Stevens L, Stigant C, Levin A: Should hemoglobin be normalized in patients with chronic kidney disease? Semin Dial 2002;15:8-13.
50. Zoccali C, Wanner C, Colasanti G, Garcia Lopez F, van der Heijden AJ, Leivestad T, MacLeod A, Stengel B, Tizard J on behalf of the ERA/EDTA Registry Committee: ERA/EDTA Registry Annual Report 2002, p 54. Accessible on ERA/EDTA webpage: www.era-edta.org
51. Van Dijk P: Mortality in the general population and its relation with RRT. XLI Congress of the ERA/EDTA, May 15-18, Lisbon 2004. Accessible at: www.era-edta.org
52. Stengel B, Billon S, van Dijk PC, Jager KC, Dekker FW, Simson K, Briggs D: Trends in incidence of renal replacement therapy for end-stage renal disease in Europe 1990-1999. Nephrol Dial Transplant 2003;8:1824-1833.
53. Collins AJ, Li S, St Peter W, Ebben J, Roberts T, Ma JZ, Manning W: Death, hospitalization, and economic associations among de novo hemodialysis patients with hematocrit values of 36-39%. J Am Soc Nephrol 2001;12:2465-2473.
54. Avram MM, Blaustein D, Fein PA, Goel N, Chattopadhyay J, Mittman N: Hemoglobin predicts long-term survival in dialysis patients: A 15-year single-center longitudinal study and a correlation trend between prealbumin and hemoglobin. Kidney Int 2003;64:S5-S11.
55. Silverberg DS, Wexler D, Blum M, et al: The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function, functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol 2000;35:1737-1744.
56. Silverberg DS, Wexler, Sheps D, et al: The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: A randomized controlled study. J Am Coll Cardiol 2001;37:1775-1780.
57. Silverberg DS, Wexler D, Blum M, et al: The effect of correction of anemia in diabetic and non-diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron. Nephrol Dial Transplant 2003;18:141-146.
58. Mancini DM, Katz SD, Lang C, et al: Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation 2003;107:294-299.
59. Siems W, Quast S, Carluccio F, Wiswedel I, Hirsch D, Augustin W, Hampl H, Riehle M, Sommerburg O: Oxidative stress in chronic renal failure as cardiovascular risk factor. Clin Nephrol 2002;58(suppl 1):12-19.